Software-delivered CBT-I for Insomnia Disorder

Last updated: August 5, 2024
Sponsor: Peking University Sixth Hospital
Overall Status: Completed

Phase

N/A

Condition

Anxiety Disorders

Treatment

software-delivered CBT-I

online PE

Clinical Study ID

NCT05747963
2022-65
  • Ages > 18
  • All Genders

Study Summary

The goal of this prospective multicenter clinical trial is to evaluate the efficacy and safety of software-delivered cognitive behavioral therapy for insomnia (CBT-I) in Chinese patients with insomnia disorder (ID). The main questions it aims to answer are: (1) whether the software-delivered CBT-I is more effective than an online patient education (online-PE) at improving insomnia. (2) whether the software-delivered CBT-I is safe for treatment of insomnia symptoms.

Participants will be randomized to receive (1) a software-delivered CBT-I using automated software called 'resleep' (one kind of digital device expected to treat insomnia targeted for Chinese patients); (2) online patient education (online-PE) about sleep.

Researchers will compare the efficacy of a software-delivered CBT-I program and an online sleep education control at improving insomnia symptoms and other psychological outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged ≥18 years old, no gender limitation;

  • Own a mobile-phone, access the Internet, and be skilled in using software;

  • Meet the diagnostic criteria of insomnia disorder in the Diagnostic and StatisticalManual of Mental Disorders (Fifth Edition) (DSM-5);

  • Insomnia symptoms appear at least 3 nights per week and last for at least 3 months;

  • ISI scores ≥ 12 ;

  • Volunteer to participate in this experiment and sign a written informed consent.

Exclusion

Exclusion Criteria:

  • Generalized Anxiety Disorder Scale-7 (GAD-7) scores ≥ 15;

  • Patients Health Questionnaire-9 (PHQ-9) scores ≥ 20;

  • Current thoughts of suicide or self-injury (defined as PHQ-9 9th item score ≥ 1);

  • Confirmed physical diseases that may affect sleep, such as congestive heart failure,chronic obstructive pulmonary disease acute phase, cardiovascular andcerebrovascular disease acute phase, etc.

  • Current diagnosed neurological or mental illness (major depressive disorder, bipolardisorder, epilepsy, schizophrenia, etc.) that may affect sleep;

  • Diagnoses of other untreated sleep disorders, such as obstructive sleep apnea,restless leg syndrome (RLS);

  • Usual bedtime (when the subject attempts to fall asleep) is earlier than 8 p.m. orlater than 2 a.m., or usual waking (arising) time is earlier than 4 a.m. or laterthan 10 a.m.

  • Alcohol or drug abusers (other than nicotine dependence) in the past year;

  • Pregnant or lactating women;

  • Undergoing systematic psychotherapy within the past 3 months;

  • Undergoing other cognitive behavioral therapy for sleep disorders;

  • Unstable usage of medication regimens that affect sleep (changes in type, dosage andmethod of use within the past 1 month);

  • Night shift workers, travelers across time zones;

  • Subjects who have not responded to previous CBT-I;

  • Other conditions deemed unsuitable for clinical trials by the investigator.

Study Design

Total Participants: 236
Treatment Group(s): 2
Primary Treatment: software-delivered CBT-I
Phase:
Study Start date:
March 21, 2023
Estimated Completion Date:
March 21, 2024

Connect with a study center

  • Peking University First Hospital

    Beijing, Beijing
    China

    Site Not Available

  • Peking University Sixth Hospital

    Beijing, Beijing 100191
    China

    Site Not Available

  • Shenzhen Kangning Hospital

    Shenzhen, Guangdong
    China

    Site Not Available

  • The Second Affiliated Hospital of AFMU

    Xi'an, Shaanxi
    China

    Site Not Available

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.